Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,081 to 2,100 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. | Hemasphere | 2018 | 31723759 | PubTator, text mining | PubMed |
| An application of the Shapley value to the analysis of co-expression networks. | Appl Netw Sci | 2018 | 30839839 | PubTator, text mining | PubMed |
| Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia. | Int J Biopharm Sci | 2018 | 30701264 | PubTator, text mining | PubMed |
| Morphologic and immunophenotypic features of a case of acute monoblastic leukemia with unusual positivity for Glycophorin-A. | Hematol Rep | 2018 | 30631409 | PubTator, text mining | PubMed |
| Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression. | Front Genet | 2018 | 30619488 | PubTator, text mining | PubMed |
| [Age-related clinical characteristics and prognosis in non-senile adults with acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2018 | 30612396 | PubTator, text mining | PubMed |
| Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients. | Cancer Cell Int | 2018 | 30598640 | PubTator, text mining | PubMed |
| Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia. | Oncotarget | 2018 | 30564301 | PubTator, text mining | PubMed |
| Translocations involving ETS family proteins in human cancer. | Integr Cancer Sci Ther | 2018 | 30542624 | PubTator, text mining | PubMed |
| Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. | Nat Commun | 2018 | 30538250 | PubTator, text mining | PubMed |
| Pre-mRNA modifications and their role in nuclear processing. | Quant Biol | 2018 | 30533247 | PubTator, text mining | PubMed |
| MEIS2 regulates endothelial to hematopoietic transition of human embryonic stem cells by targeting TAL1. | Stem Cell Res Ther | 2018 | 30526668 | PubTator, text mining | PubMed |
| Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. | Int J Mol Sci | 2018 | 30513905 | PubTator, text mining | PubMed |
| Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. | Nucleic Acids Res | 2018 | 30500954 | PubTator, text mining | PubMed |
| High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. | EBioMedicine | 2018 | 30472087 | PubTator, text mining | PubMed |
| NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. | Cancer Manag Res | 2018 | 30464604 | PubTator, text mining | PubMed |
| Molecular landscape and targeted therapy of acute myeloid leukemia. | Biomark Res | 2018 | 30455953 | PubTator, text mining | PubMed |
| Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. | Oncotarget | 2018 | 30450160 | PubTator, text mining | PubMed |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. | Lancet Oncol | 2018 | 30442503 | PubTator, text mining | PubMed |
| JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. | Cancer Cell | 2018 | 30423295 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=105